You’re in your mid-40s. You’re running a business. You’re training regularly. And something has shifted — you can’t quite identify it, but the energy isn’t the same, the recovery takes longer, your body composition is changing despite “doing everything right,” and your motivation for things that used to drive you has dulled.
Your doctor checks your total testosterone. It comes back at 385 ng/dL — technically “normal.” You’re told everything is fine.
Here’s what your doctor didn’t measure: your free testosterone (the biologically active fraction), your SHBG (which determines how much testosterone is actually available to your tissues), your DHEA-S (the adrenal precursor hormone that supports testosterone production and has independent effects on aging), or your estradiol (which rises relative to testosterone as men age and contributes to body fat accumulation and libido changes).
Male hormonal health at 40+ is not a single number. It’s a system — and optimizing that system requires measuring the whole system.
The Physiology: How Testosterone Changes After 40
Testosterone is produced primarily in the testes (Leydig cells), controlled by the hypothalamic-pituitary-testicular (HPT) axis. Production peaks in the late teens to early 20s and begins a slow, progressive decline that continues across the remaining decades of a man’s life.
The data on this decline is consistent across studies: total serum testosterone in men aged 40–70 decreases at a rate of approximately 0.4% annually, while free testosterone — the biologically active fraction — declines at 1.3% per year (Reproductive Biology and Endocrinology, 2024). The distinction matters enormously, and it is a distinction that standard care almost universally fails to make.
By age 45–49, between 6–12% of men have biochemically low testosterone levels, though that percentage rises substantially with comorbidities. In primary care settings, approximately 38.7% of men aged 45 and older have total testosterone below 300 ng/dL — the clinical hypogonadism threshold — according to the HIM Study published in the International Journal of Clinical Practice (2006).
The reason free testosterone declines faster than total testosterone lies in a protein called SHBG — sex hormone-binding globulin. SHBG increases with age and binds testosterone tightly, rendering it biologically inactive. As SHBG rises, a higher proportion of total testosterone is “bound” and unavailable for tissue uptake. A man can have a total testosterone of 450 ng/dL but a free testosterone in the low-normal or below-normal range if his SHBG is elevated — and his tissues will respond accordingly.
This is the most common clinical error in male hormone assessment: measuring total testosterone only and declaring everything normal without accounting for SHBG. It is a mistake that leaves the most functionally relevant piece of the hormonal picture entirely unmeasured.
The Complete Hormone Panel for Men Over 40
A comprehensive male hormone evaluation is not one number — it is a system-level assessment. At minimum, it should include the following:
- Total testosterone (early morning, 7–10 a.m. — levels fluctuate by 30–35% diurnally, meaning an afternoon draw on the same day can show “low” in a man whose morning level is entirely normal)
- Free testosterone (calculated or, ideally, measured via equilibrium dialysis — the gold standard method)
- SHBG — to interpret the total/free relationship and understand the binding dynamics
- Estradiol (sensitive LC-MS/MS assay, not standard immunoassay) — elevated estradiol in men contributes to gynecomastia, libido suppression, and fat accumulation; standard immunoassays are unreliable at male-range concentrations
- DHEA-S — the adrenal precursor hormone; declines with age and has independent effects on metabolic health, inflammation, and cognitive function
- LH and FSH — to distinguish primary (testicular) from secondary (pituitary/hypothalamic) hypogonadism, which determines the appropriate treatment pathway
- Prolactin — elevated prolactin suppresses the HPT axis and can masquerade as hypogonadism; a pituitary microadenoma must be ruled out before initiating TRT
- Thyroid panel (TSH, free T3, free T4) — thyroid dysfunction profoundly affects energy, body composition, and mood, and is frequently misattributed to low testosterone
- Cortisol — chronic cortisol elevation directly suppresses testosterone production; diurnal cortisol patterns are informative and frequently overlooked
The Evidence on Testosterone Replacement Therapy
Who Is a Candidate?
The clinical guideline threshold for TRT initiation is total testosterone below 300 ng/dL on two early-morning measurements, with compatible symptoms. Symptoms must be present — biochemical hypogonadism without clinical symptoms is not generally an indication for TRT. The Endocrine Society and American Urological Association both require both criteria to be met before initiating therapy.
For men aged 40–49 specifically, a 2025 narrative review in Cureus found that TRT is most beneficial in men with biochemically confirmed hypogonadism. Documented improvements with appropriate TRT include:
- Sexual function: IIEF score gains of 4–7 points
- Lean mass gains of 2–4 kg
- Fat mass reductions of 2–3 kg
- Annual bone mineral density gains of approximately 5% with sustained treatment
- Reduction in progression to type 2 diabetes by 40% when combined with structured lifestyle interventions, as demonstrated in the T4DM trial
These are meaningful clinical outcomes — but they apply to men with confirmed hypogonadism. The evidence is substantially weaker for men with testosterone levels in the normal range who seek TRT for performance or optimization purposes.
Cardiovascular Safety: The TRAVERSE Trial
The landmark TRAVERSE trial — a randomized, double-blind, placebo-controlled cardiovascular safety study — enrolled 5,204 men ages 45–80 with documented hypogonadism and preexisting or high cardiovascular risk. Mean follow-up was 33 months.
The primary cardiovascular safety endpoint — death from CV causes, nonfatal MI, or nonfatal stroke — occurred in 7.0% of the testosterone group versus 7.3% in the placebo group (hazard ratio 0.96; 95% CI: 0.78–1.17). Testosterone was non-inferior to placebo for major adverse cardiovascular events. This was a definitive finding from the largest TRT cardiovascular safety trial ever conducted.
Notable adverse events with testosterone versus placebo included atrial fibrillation (3.5% vs. 2.4%), acute kidney injury (2.3% vs. 1.5%), and pulmonary embolism (0.9% vs. 0.5%). These findings require clinical attention and appropriate monitoring protocols — but they did not negate the overall cardiovascular safety finding for appropriately selected patients.
A 2025 systematic review of 25 studies on cardiovascular effects of TRT in hypogonadal men found that TRT improved lipid profiles (reduced total and LDL cholesterol), reduced inflammatory markers (CRP, IL-6, TNF-α), improved endothelial function, and showed no compelling evidence of increased cardiovascular risk at physiological dosing (Cureus, 2025). The cardiovascular picture with TRT is more nuanced than early observational studies suggested — and the randomized controlled data is substantially more reassuring.
Evidence-Based Non-TRT Interventions
Before initiating TRT — and as ongoing foundations during any hormonal protocol — evidence-based lifestyle interventions should be systematically optimized. These are not adjuncts. For men with mild or borderline hypogonadism, they are often the primary treatment:
- Sleep optimization: Poor sleep is one of the strongest independent drivers of testosterone decline. A week of 5-hour sleep nights reduces testosterone by approximately 15% in young healthy men — a magnitude of hormonal suppression that no supplement or nutraceutical can compensate for.
- Resistance training: Three or more sessions per week of progressive resistance training consistently supports testosterone levels and is the most impactful exercise modality for hormonal health. It also improves insulin sensitivity, reduces visceral fat, and builds the lean mass that testosterone is meant to maintain.
- Body fat reduction: Visceral fat converts testosterone to estradiol via the aromatase enzyme. Reducing visceral fat reduces estradiol, freeing up existing testosterone — often normalizing mild hypogonadism without any pharmacological intervention.
- Stress and cortisol management: Chronic cortisol elevation directly suppresses LH pulsatility and testosterone production through HPT axis inhibition. Men under sustained psychological or physiological stress often have measurably lower testosterone independent of age-related decline.
- Zinc and vitamin D: Both are required cofactors for testosterone synthesis. Deficiencies are common in the executive demographic and correctible — and both deficiencies can produce testosterone levels meaningfully below an individual’s genetic potential.
“Male hormonal health at 40 is not a single number — it’s a system, and optimizing that system requires measuring the whole system.”
What Testosterone Isn’t — And What We’re Still Learning
Honest caveat: TRT is not a fountain of youth for men with normal testosterone. The documented benefits are consistent in men with biochemically confirmed hypogonadism and compatible symptoms. Men with testosterone in the normal range who pursue TRT for performance enhancement are using it off-label — the data is weaker, and the risks (fertility suppression, erythrocytosis, long-term unknown effects) still apply without the same evidence of benefit.
Fertility is a particularly important consideration. Exogenous testosterone suppresses spermatogenesis by inhibiting the HPT axis. More than 90% of men develop oligospermia or azoospermia during TRT — a clinically significant and often underappreciated consequence. This is highly relevant for men in their 40s who may still be considering paternity. Alternatives that preserve fertility — clomiphene citrate, human chorionic gonadotropin (hCG) — exist and should be discussed in detail before initiating any testosterone protocol.
We are also still learning about the long-term effects of decades-long TRT exposure. Most studies follow patients for two to four years. The 30-year safety profile — the profile relevant for a 45-year-old who initiates TRT and maintains it through his 70s — is not yet established. Clinical humility about what we don’t yet know is part of responsible hormonal medicine.
The Gap in Standard Care
The average internist or family medicine physician will check total testosterone if the patient explicitly requests it — and then interpret the result against a broad “normal range” that includes values most longevity practitioners would consider suboptimal. Free testosterone and SHBG are rarely checked. DHEA-S is virtually never ordered in primary care. Estradiol in men is almost never assessed. Cortisol patterns go unmeasured entirely.
The result: a 48-year-old man with total testosterone of 380, free testosterone of 7.2 pg/mL, SHBG of 48, and elevated estradiol from visceral fat aromatization gets told “your testosterone is fine.” His symptoms — fatigue, body composition change, declining motivation — are attributed to “stress” or “normal aging.” He leaves the appointment with no actionable information.
They may be, in part, attributable to those factors. But they may also have a measurable, addressable hormonal component that a complete evaluation would identify — and that, once identified, can be systematically addressed. The difference between “normal aging” and “a correctable hormonal pattern” is not always visible with a single total testosterone measurement. It requires the full panel.
How We Assess Male Hormones at Pravida Health
Comprehensive hormone analysis is available across Pravida Health membership tiers. Our evaluation includes the complete panel described above — total and free testosterone, SHBG, estradiol (LC-MS/MS), DHEA-S, LH, FSH, prolactin, and a complete thyroid panel — alongside metabolic biomarkers, body composition by DEXA, and cardiovascular risk markers. We read these results as a system, not as isolated numbers.
When we find low-normal testosterone with elevated SHBG, we address SHBG before jumping to TRT — because the first priority is identifying whether SHBG can be reduced through insulin resistance treatment, weight loss, or thyroid optimization, freeing up the testosterone that is already present. This approach frequently resolves symptomatic hypogonadism without pharmacological intervention.
When TRT is appropriate and clinically indicated, we manage it with careful monitoring: testosterone levels every three months initially, hematocrit and hemoglobin monitoring for erythrocytosis, PSA monitoring, estradiol management to prevent excessive aromatization, and regular blood pressure assessment. Monitoring is not optional — it is what makes TRT safe and sustainable over the long term.
We also support patients through the fertility implications of TRT, using clomiphene or hCG protocols for men who wish to preserve fertility potential while addressing the hormonal picture. Schedule a consultation to discuss which approach is appropriate for your goals and clinical situation.
What You Can Do Today
- Get a complete hormone panel — not just total testosterone. Ask specifically for: total testosterone (early morning draw), free testosterone, SHBG, estradiol (sensitive assay), DHEA-S, LH, FSH, and TSH. This is the minimum for meaningful hormone assessment. Total testosterone alone is insufficient for clinical decision-making.
- Optimize the lifestyle foundations first. Sleep 7–9 hours. Perform progressive resistance training 3+ days per week. Reduce visceral fat. Manage chronic stress. These interventions frequently normalize mild hormonal imbalances without pharmacological intervention — and they are foundational to any hormonal protocol regardless.
- Consider the timing of your testosterone test. Total testosterone peaks in the early morning and declines by 30–35% through the afternoon. A 9 a.m. draw and a 3 p.m. draw on the same day can show “normal” and “low” in the same person. Always test early morning, and always test twice before making clinical decisions.
- Don’t ignore thyroid. Hypothyroidism and subclinical hypothyroidism produce fatigue, weight gain, reduced motivation, and cognitive fog that are clinically indistinguishable from hypogonadism. Both conditions should be assessed simultaneously — and both require treatment if present.
- Find a physician who measures and interprets the complete panel. The single most important step is comprehensive assessment by a practitioner who understands hormonal systems — not just a testosterone number in isolation. Book a consultation at Pravida Health to start with the full picture.
Frequently Asked Questions
What is a normal testosterone level for a man in his 40s?
Standard laboratory reference ranges are typically 300–1,000 ng/dL for total testosterone, but these ranges are population-based and include many symptomatic individuals. For men in their 40s, most longevity medicine practitioners consider a total testosterone above 500–600 ng/dL — with free testosterone above 10–15 pg/mL — as associated with better symptom profiles and metabolic health. Symptoms and free testosterone matter more than total testosterone alone. A number within the laboratory reference range is not the same as a number that reflects hormonal excellence.
Is testosterone replacement therapy safe for cardiovascular health?
The TRAVERSE trial — the largest randomized controlled trial of TRT cardiovascular safety, with 5,204 participants and 33 months of follow-up — demonstrated that TRT was non-inferior to placebo for major adverse cardiovascular events in men with hypogonadism. TRT was associated with small but statistically significant increases in atrial fibrillation, acute kidney injury, and pulmonary embolism. The current clinical consensus is that TRT in appropriately selected hypogonadal men, with proper monitoring, does not meaningfully increase cardiovascular risk — but those monitoring requirements are real and should not be skipped.
What is SHBG and why does it matter?
Sex hormone-binding globulin (SHBG) is a protein that binds testosterone and makes it biologically unavailable to tissues. As SHBG rises with age, an increasing proportion of total testosterone is bound — reducing the bioavailable (free) fraction that actually enters cells and produces hormonal effects. Men can have normal or even high-normal total testosterone but functionally low free testosterone if SHBG is elevated. Measuring SHBG is essential for complete hormone interpretation — and omitting it is the most common reason a man gets told his “testosterone is fine” when his tissues are experiencing functional deficiency.
What is DHEA-S and should men test it?
DHEA-S (dehydroepiandrosterone sulfate) is the most abundant circulating steroid hormone in the human body and an adrenal precursor to both testosterone and estrogen. It declines progressively with age — often by 80–90% between ages 25 and 70 — and has independent associations with metabolic health, immune function, and cognitive performance beyond its role as a hormonal precursor. Men over 40 should include DHEA-S in a comprehensive hormone evaluation. It is inexpensive to measure and provides clinically meaningful information that total testosterone cannot capture.
Does TRT affect fertility?
Yes — significantly. Exogenous testosterone suppresses the HPT axis and reduces gonadotropin (LH and FSH) production, leading to impaired spermatogenesis. More than 90% of men on TRT develop oligospermia or azoospermia — often within three to six months of initiating therapy. Men wishing to preserve fertility while addressing low testosterone should discuss alternative protocols — clomiphene citrate or hCG-based approaches — with their physician. These alternatives stimulate endogenous testosterone production while preserving sperm production, and they are a legitimate option for men in their 40s who have not completed their families.
Want a Complete, Evidence-Based Male Hormone Evaluation?
Schedule a consultation at Pravida Health, where we assess the full hormonal system — not just a single number. We’ll build a personalized plan around your complete panel.
Book a Consultation View Memberships